Johnson & Johnson

Johnson & Johnson (NYSE:JNJ) is expanding in Wilson County, North Carolina, with a new multibillion-dollar pharmaceutical facility. The company expects to create up to 500 new jobs in the community through the project in Wilson. It marks the second time in 14 months that J&J has announced a significant project in the area after a…

Johnson & Johnson (NYSE:JNJ) announced today that it plans to increase its biopharmaceutical manufacturing presence in North Carolina. The company committed $2 billion toward a 160,000+-square-foot dedicated manufacturing facility at Fujifilm’s new biopharmaceutical manufacturing site in Holly Springs, North Carolina. Its commitment spans the next 10 years, expanding its U.S. manufacturing capacity and creating approximately…

Johnson & Johnson today announced it broke ground on a $2 billion biologics manufacturing facility in Wilson, N.C., a small portion of the company’s $55 billion U.S. investment initiative over the next four years. The 500,000 ft² facility will expand the company’s capacity to develop and produce advanced therapies for oncology, immunology and neurological diseases.…

Johnson & Johnson recently announced plans to invest more than $2 billion in a new manufacturing facility in North Carolina. The company plans to build a state-of-the-art biologics manufacturing facility in Wilson, North Carolina, to expand the production of its pipeline of innovative biologics. The expansion supports J&J’s broader plan to advance more than 70…

Johnson & Johnson has sold off its remaining stake in the Kenvue consumer products business it spun off last year. In a filing with the SEC today, J&J said it brought in $3.6 billion for general corporate purposes from the transaction. Johnson & Johnson brought in the cash on May 15 after it issued a…

Johnson & Johnson has announced its first earnings following its decision to rebrand its pharma segment as Johnson & Johnson Innovative Medicine in September. In the third quarter of 2023, the company reported sales growth of 6.8%, amounting to $21.4 billion.  The bestseller for the company was Stelara with sales amounting to $2.864 billion. J&J’s…

Both Johnson & Johnson and Pfizer are gearing up to release third-quarter results. While J&J continues to display resilience with its diverse portfolio, Pfizer continues to face challenges with waning demand for its COVID-19 therapies. To date, Pfizer’s stock is down by roughly a third so far this year, reflecting concerns over its ability to…

A U.S. bankruptcy judge in New Jersey has dismissed a Johnson & Johnson-created company’s bankruptcy filing to resolve talc-related lawsuits. Judge Michael Kaplan’s ruling on July 28 was similar to a U.S. Court of Appeals for the Third Circuit ruling months ago, which failed to find immediate financial distress over the lawsuits. As recounted in…

Johnson & Johnson continues to face legal challenges over allegations that its talcum powder causes cancer. Recently, a judge dismissed the company’s latest attempt to settle thousands of lawsuits through bankruptcy, marking the second time J&J’s bankruptcy strategy has been rebuffed. We take a look at the timeline of the talc litigation below. Johnson &…

Johnson & Johnson (NYSE:JNJ) today reported Q4 results that beat The Street on earnings but missed on revenue amid continued macroeconomic challenges. The company’s Pharmaceutical business saw sales grow 6.8%. Pharma growth drivers included: Darzalex (daratumumab), a biologic for the treatment of multiple myeloma; Stelara (ustekinumab), a biologic for the treatment of a number of…